The most powerful conversations at BIO won't start with "here's what we do." They start with a reframe that changes how the other side sees their own situation, fit to that firm's economics, with the choice made concrete enough to act on.
For ProTGen at BIO, the insight is not about Notch or about longevity. It is about which audience door funds the next eighteen months on the best terms.
Most of the partners you'll meet at BIO have been trained to ask, "what's the mechanism, what's the first indication, what's the IP?", in that order. They are pattern-matching to a cell therapy or hematology template. Inside that pattern, ProTGen is a credible but crowded entrant: another novel-mechanism platform with one program in development.
There is a second pattern, less crowded and substantially better capitalized in 2026, that asks, "what is the upstream driver of the decline you're addressing, and is your intervention specific enough to credibly modulate it without breaking adjacent biology?" That is the pattern longevity capital (Hevolution, certain Khosla and NEA partners, the Saudi sovereign aging funds, the Altos-adjacent investor network) has been trained on. Inside that pattern, ProTGen is not "another cell therapy company." It is one of a very small number of programs that has a targeted way to act on thymic involution, with a hard clinical proof point that traditional aging-biology companies cannot produce.
The move is not to abandon Notch. It is to recognize that the same molecule walks into a different valuation conversation depending on which sentence the room is repeating about you when you leave.
What's the IND timeline for ProT-096?,
r: What's the cleanest preclinical signal that targeted Notch activation specifically restores thymic function, not just T-cell output?
,
},
{
l: How does manufacturing scale in personalized cell therapy?
,
r: What does the dose-response look like? What's the off-target risk profile across other Notch-dependent tissues?
,
},
{
l: What's the competitive landscape against ex vivo T-cell engineering?
,
r: What's your second indication, and is it in aging biology or still in oncology?
,
},
{
l: What's the partnership structure with Cellares?
,
r: Who in your scientific advisory board has direct credibility in aging biology, not just hematology?
,
},
{
l: Where does the platform go after ProT-096?
,
r: What's the smallest piece of human data that would let you raise a longevity-themed round at a longevity multiple?
,
},
]} />
These are not better or worse questions. They are different vocabularies. Walking into the wrong one with the wrong materials costs a meeting. Walking into the right one with the right materials compounds.
{/* ===================== Three-word test ===================== */}
Three-word test (predictions)
If we ran the 90-second retell test on each version of the story today, here is what we'd expect three smart listeners to come back with:
Notch frame today: "Notch, T-cells, leukemia." Accurate. Crowded. Hard to differentiate from a half-dozen other entrants in cell therapy.
Notch frame done well: "Targeted, clinical, credible." This is the version where the mechanism story does the differentiation work.
Longevity frame today: "Thymus, aging, ambitious." Memorable but at risk of sounding like a category claim without proof.
Longevity frame done well: "Upstream, specific, proven-in-extremis." The third word is the load-bearing one: without ProT-096 in refractory hematologic malignancies as the hard validation, the longevity story drifts into territory longevity capital has been burned by before.
The good news: ProT-096 carries the proof burden in both frames. It is the same wedge. The frame only changes the room it's pointed at.
{/* ===================== What to do with this at BIO ===================== */}
What to do with this at BIO
A few suggestions, lightly held:
Read it once on the plane, then put it away. This is a thinking tool, not a script. The point is to know which door you're choosing to walk through in each meeting, not to memorize a new pitch.
Test the cognition cheaply. If you have a partner meeting where the stakes are lower, try the longevity frame in the opening sixty seconds and watch what they ask next. The kind of question that comes back tells you which door their organization is wired for. We've seen this kind of cheap A/B test give a founder more strategic clarity than three weeks of internal strategy work.
Notice who asks about thymic biology unprompted. That person is almost always the one driving aging-related diligence in their organization, whether or not their fund has a formal longevity thesis. They are worth a follow-up after BIO.
Don't try to be both at once. The temptation will be to write a one-pager that "covers both." The result is a one-pager that lands as neither: too speculative for the cell therapy audience, too cautious for the longevity audience. The category hierarchy chooses the room. The room chooses the proof bar.
{/* ===================== A note on what comes next ===================== */}
A note on what comes next
This is a working document for your use, not a proposal. You have the engagement letter to review whenever it's the right time; that conversation can wait until after BIO without losing anything. What matters this week is that you walk into your meetings with options you can see, not just options you have.
If the comparison above is useful, that's the point. If a particular frame is clearly wrong for ProTGen's current moment and we've missed something, tell us: what we built on this side of the table is only as good as the substrate you can see that we can't.
Travel well.
Daniel, Eric, and Dave
Dark Horse Works
Dark Horse Works · Daniel Behr, Eric Eskey, David Potter
protgen.darkhorse.works